Beyond the Typical ICANS: Characterizing Non-ICANS Neurological Complications in CAR-T Therapy – A Retrospective Analysis
Clicks: 2
ID: 323806
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #98 of 105 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory hematologic malignancies. While Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a well-recognized complication, expanding clinical use has revealed distinct non-ICANS neurological complications that challenge standard diagnostic and management approaches. We characterize the clinical features and outcomes of these non-classic presentations. Methods A retrospective analysis was conducted on 357 patients receiving commercial CAR-T therapy for Non-Hodgkin Lymphoma or Multiple Myeloma at a single academic center (2015–2025). Non-ICANS neurological complications were defined by neurologic deficits, movement disorders, or neurocognitive syndromes occurring in the absence of global encephalopathy (ICE scores 9–10). Institutional protocol included baseline neurology evaluation and brain MRI. Results Non-ICANS complications occurred in 17 patients (4.76%). Manifestations included focal neuropathies or myelopathy (n = 5), progressive leukoencephalopathy (n = 4), neuropsychiatric symptoms (n = 3), Parkinsonism (n = 2), and cranial nerve palsies (n = 4). Compared to the institutional median for classic ICANS (7 days), non-ICANS demonstrated a prolonged median duration of 14 days (range, 4–365+ days). Abnormal brain MRI findings were present in 5 of 15 (33.3%) cases with post-treatment brain MRI, manifesting commonly as T2/FLAIR hyperintensities in the white matter. CSF immunomonitoring in a subset of cases (n = 2) revealed an enrichment of CAR T-cells compared to peripheral blood. Conclusions Non-ICANS neurological complications represent a distinct clinical subset characterized by atypical findings, neuroimaging abnormalities, and/or protracted recovery. Increased clinical vigilance and tailored diagnostic approaches are essential to mitigate long-term morbidity, as standard screening tools fail to capture these focal neurotoxicities.
| Reference Key |
openalex_W7172482055
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Melissa A. Nicholas, Abdulaziz Abu-Haimed, Faisal Abushullaih, Emily N. Davidson, Graeme Fenton, Justin W. Kehm, Hakan Koçoğlu, Jean A Yared, Ariel Fromowitz, Nancy M. Hardy, Aaron P. Rapoport, Djordje Atanackovic, Lily Pham, A. Badros, Haroon Ahmad |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag204
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.